Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now directly owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Xeris Biopharma Trading Up 7.0 %
Xeris Biopharma stock opened at $5.81 on Friday. The company has a market capitalization of $894.39 million, a PE ratio of -12.91 and a beta of 2.32. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.69 and a 12 month high of $5.92. The stock has a 50-day moving average price of $3.88 and a two-hundred day moving average price of $3.40.
Institutional Investors Weigh In On Xeris Biopharma
Institutional investors and hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at about $34,000. R Squared Ltd acquired a new stake in Xeris Biopharma during the fourth quarter worth approximately $42,000. Quantbot Technologies LP acquired a new stake in Xeris Biopharma during the third quarter worth approximately $44,000. Cibc World Markets Corp acquired a new stake in Xeris Biopharma during the fourth quarter worth approximately $44,000. Finally, Raymond James Financial Inc. acquired a new stake in Xeris Biopharma during the fourth quarter worth approximately $45,000. Institutional investors and hedge funds own 42.75% of the company's stock.
Wall Street Analyst Weigh In
XERS has been the topic of several analyst reports. Jefferies Financial Group reissued a "buy" rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Craig Hallum increased their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a report on Friday, March 7th. Leerink Partners increased their target price on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Piper Sandler restated a "neutral" rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, HC Wainwright restated a "buy" rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $5.92.
Check Out Our Latest Analysis on Xeris Biopharma
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
